Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin)
- 1 October 1994
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 41 (4) , 539-541
- https://doi.org/10.1111/j.1365-2265.1994.tb02589.x
Abstract
Hexarelin is a new synthetic growth hormone releasing peptide. We have tested the efficacy of intranasal (i.n.) administration of hexarelin to stimulate plasma GH and have compared this to the intravenous (i.v.) administration of the peptide. Ten children with familial short stature (FSS) aged 5.5-15.5 years and two known GH deficient patients aged 24 and 28 years without GH treatment. All 12 subjects were submitted to i.v. (1 microgram/kg) and i.n. (20 micrograms/kg) hexarelin tests with a one-week interval between tests. Blood samples for GH, TSH, fT4 and T3 were obtained at 0, 15, 30, 60, 90 and 120 minutes. The hormone determinations were made by standard radio-immunoassays (RIA). Both the i.n. and i.v. administration of hexarelin induced a large GH response, the mean (+/- SD) being 72.2 +/- 35.5 mU/l for the i.n. test and 79.6 +/- 53.0 mU/l for the i.v. test. The peak GH in the i.v. test occurred at 15-30 minutes and in the i.n. test between 30 and 60 minutes. The GH deficient patients showed no GH response in either test. Plasma TSH decreased in the FSS children from a mean (+/- SD) of 1.0 +/- 0.26 to 0.64 +/- 0.2 mU/l (P < 0.005) during the i.n. test and from 1.0 +/- 0.3 to 0.7 +/- 0.3 mU/l (P < 0.05) during the i.v. test. In the isolated GH deficient patient, plasma TSH decreased from 1.06 +/- 0.38 mU/l to 0.86 +/- 0.17 during the i.v. test and from 1.60 +/- 0.01 to 1.11 +/- 0.06 mU/l during the i.n. test. There were no significant changes in plasma fT4 or T3 in any of the tests. The synthetic hexapeptide hexarelin is a potent pituitary GH stimulator when administered intranasally. The GH response was similar to that observed after intravenous hexarelin. Simultaneously, there was a significant decrease in plasma TSH but the concentrations remained in the normal range. These findings appear to be of theoretical and practical relevance to the investigation and management of short children.Keywords
This publication has 9 references indexed in Scilit:
- GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult ratsLife Sciences, 1994
- Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescentsActa Endocrinologica, 1993
- Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic childrenJournal of Endocrinological Investigation, 1993
- Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP‐6Clinical Endocrinology, 1993
- Intravenous administration of recombinant IGF-I lowers serum GHRH and TSHActa Endocrinologica, 1990
- Growth Hormone (GH)-Releasing Peptide Stimulates GH Release in Normal Men and Acts Synergistically with GH-Releasing Hormone*Journal of Clinical Endocrinology & Metabolism, 1990
- Circadian Variation of Thyrotropin in ChildhoodJournal of Clinical Endocrinology & Metabolism, 1989
- Growth hormone releasing hormone (GH-RH, GRF)?an important new clinical toolEuropean Journal of Pediatrics, 1986
- On thein Vitroandin VivoActivity of a New Synthetic Hexapeptide that Acts on the Pituitary to Specifically Release Growth Hormone*Endocrinology, 1984